Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
Explore this paper's citation graph
Summary
A mixed response to pembrolizumab in advanced UC was not uncommon and the OS of the MR group tended to be similar to that of the SD and PD response groups.
- Type
- article
- Published
- 2021-01-01
- Cited by
- 8
- References
- 26
- Access
- Open access
- OpenAlex
- https://openalex.org/W3194663175
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:237154829
Keywords
Pembrolizumab, Medicine, Progressive disease, Complete response, Internal medicine
References
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- The future of immune checkpoint therapy
- Pseudoprogression and Immune-Related Response in Solid Tumors.
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
- Emerging immunotherapies for bladder cancer
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
- Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
- TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Pseudoprogression and hyperprogression after checkpoint blockade
- Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
- Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
- Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Cited by
- Diabetes Mellitus Causes Male Reproductive Dysfunction: A Review of the Evidence and Mechanisms
- Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
- Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
- Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study
- Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer
- Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
- Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
- Clinical Implications of Mixed Response on Prognosis of Non-Small Cell Lung Cancer (Nsclc) Patients Treated with Immunotherapy
Related papers
- CO153 Survival Analyses and Indirect Treatment Comparisons (ITCS) in First-Line Metastatic Urothelial Carcinoma (1L MUC)
- Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC)
- The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder
- Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial
- Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder
- A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma.
- Histologic Variants of Infiltrating Urothelial Carcinoma
- 1744P Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study